Marshall Edwards, Inc. (NASDAQ:MSHL)
Industry: Healthcare

Listed 11 Consecutive Market Days. On List as of 02/06/2012 Through 02/22/2012

Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.

Current Quote*
Last: $Unk
Change: 0.000
Book: $5.100
Volume: Unk

As Of: 08/30 13:17 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol MSHL

  • No BuyIns.Net Alerts Available for MSHL

Graphs for MSHL

3 Month Graph

6 Month Graph

1 Year Graph